Compare Medpace Holdings Inc (MEDP) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs T Rowe Price Group Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while T Rowe Price Group Inc trades at $105.16 (market cap $22.23B). The key difference: T Rowe Price Group Inc is the larger of the two by market cap, and T Rowe Price Group Inc pays a 4.99% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and T Rowe Price Group Inc for 115 Days on average.
| MEDP | TROW | |
|---|---|---|
Market Cap | $16.82B | $22.23B |
Volume | 223,093 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $630.19 | $121.68 |
52-Week Low | $393.42 | $86.19 |
Typical Hold Time | 14 Days | 115 Days |
Enterprise Value | $16.44B | $19.43B |
Dividend Yield | — | 4.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
T. Rowe Price Group (TROW) trades at $104.23, up 0.15% on the day, with a bearish technical signal but solid fundamentals. The stock shows consistent revenue growth, reaching $7.31B in 2025, and a strong net income margin of 29.26%. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 40-year dividend growth streak, paying $1.30 per share in H2 2026. Analyst consensus is mixed, with a $110.50 price target, but technical indicators point to near-term resistance at $105.
Outlook: TROW offers value with a low P/E of 10.46 and robust profitability, but faces headwinds from net outflows and bearish technicals. Investment opportunity lies in its dividend aristocrat status and earnings momentum, while risks include fee pressure from market volatility and competitive threats. The stock is a hold for income investors, with upside potential if operational trends improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
